Who are Taxol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Taxol, Taxol, Klisyri, Halaven, Jevtana Kit, Ixempra Kit.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nabpaclitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Taxol — Competitive Intelligence Brief

Taxol (Nabpaclitaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microtubule Inhibitor. Area: Oncology.

discontinued Microtubule Inhibitor Tubulin beta-3 chain Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Taxol (Nabpaclitaxel) — Pfizer. Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Taxol TARGET	Nabpaclitaxel	Pfizer	discontinued	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
Taxol	nab-paclitaxel	Pfizer	marketed	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
Taxol	paclitaxel	Pfizer	marketed	Microtubule Inhibitor [EPC]	Tubulin beta-3 chain	1992-01-01
Klisyri	TIRBANIBULIN	Almirall	marketed	Microtubule Inhibitor [EPC]	Tyrosine-protein kinase Lyn	2020-01-01
Halaven	ERIBULIN	Eisai	marketed	Microtubule Inhibitor	Tubulin beta	2010-01-01
Jevtana Kit	cabazitaxel	Accord Hlthcare	marketed	Microtubule Inhibitor	Tubulin beta	2010-01-01
Ixempra Kit	IXABEPILONE	R-Pharm Us Llc	marketed	Microtubule Inhibitor	Apoptosis regulator Bcl-2	2007-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-10 — Jevtana Kit · 7241907*PED · Compound · US
2026-08-13 — Taxol · 8034375 · Method of Use · US
2026-08-13 — Taxol · 8034375 · US
2026-08-13 — Taxol · 8034375 · US
2026-08-21 — Taxol · 7758891*PED · US
2026-08-21 — Taxol · 9101543*PED · US
2026-08-21 — Taxol · 9101543*PED · US
2026-08-21 — Taxol · 9101543*PED · Compound · US
2026-08-21 — Taxol · 7758891*PED · Compound · US
2026-08-21 — Taxol · 8268348*PED · Compound · US
2026-08-21 — Taxol · 7758891*PED · US
2026-08-21 — Taxol · 8268348*PED · US
2026-08-21 — Taxol · 8268348*PED · US
2027-02-13 — Taxol · 8034375*PED · US
2027-02-13 — Taxol · 8034375*PED · Compound · US
2027-02-13 — Taxol · 8034375*PED · US
2030-10-27 — Jevtana Kit · 8927592 · Method of Use · US
2030-10-27 — Jevtana Kit · 12453712 · Method of Use · US
2030-10-27 — Jevtana Kit · 10716777 · Method of Use · US
2030-10-27 — Jevtana Kit · 10583110 · Method of Use · US
2031-04-27 — Jevtana Kit · 12453712*PED · Compound · US
2031-04-27 — Jevtana Kit · 8927592*PED · Compound · US
2031-04-27 — Jevtana Kit · 10583110*PED · Compound · US
2031-04-27 — Jevtana Kit · 10716777*PED · Compound · US
2032-03-04 — Taxol · 9393318 · US
2032-03-04 — Taxol · 9597409 · US
2032-03-04 — Taxol · 9393318 · US
2032-03-04 — Taxol · 9393318 · Method of Use · US
2032-03-04 — Taxol · 9597409 · Method of Use · US
2032-03-04 — Taxol · 9597409 · US

Sponsor landscape (Microtubule Inhibitor class)

Pfizer · 2 drugs in this class
Accord Hlthcare · 1 drug in this class
Eisai · 1 drug in this class
R-Pharm Us Llc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Taxol — Competitive Intelligence Brief. https://druglandscape.com/ci/nabpaclitaxel. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab